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Abstract
The neural crest (NC) is a population of embryonic stem cells that gives rise to numerous cell types, including the glia and
neurons of the peripheral and enteric nervous systems and the melanocytes of the skin and hair. Mutations in genes and
genetic pathways regulating NC development lead to a wide spectrum of human developmental disorders collectively
called neurocristopathies. To identify molecular pathways regulating NC development and to understand how alterations in
these processes lead to disease, we established an N-ethyl-N-nitrosourea (ENU) mutagenesis screen utilizing a mouse model
sensitized for NC defects, Sox10
LacZ/+. Out of 71 pedigrees analyzed, we identified and mapped four heritable loci, called
modifier of Sox10 expression pattern 1–4 (msp1–4), which show altered NC patterning. In homozygous msp1 embryos,
Sox10
LacZ expression is absent in cranial ganglia, cranial nerves, and the sympathetic chain; however, the development of
other Sox10-expressing cells appears unaffected by the mutation. Linkage analysis, sequencing, and complementation
testing confirmed that msp1 is a new allele of the receptor tyrosine kinase Erbb3, Erbb3
msp1, that carries a single amino acid
substitution in the extracellular region of the protein. The ENU-induced mutation does not alter protein expression,
however, it is sufficient to impair ERBB3 signaling such that the embryonic defects observed in msp1 resemble those of
Erbb3 null alleles. Biochemical analysis of the mutant protein showed that ERBB3 is expressed on the cell surface, but its
ligand-induced phosphorylation is dramatically reduced by the msp1 mutation. These findings highlight the importance of
the mutated residue for ERBB3 receptor function and activation. This study underscores the utility of using an ENU
mutagenesis to identify genetic pathways regulating NC development and to dissect the roles of discrete protein domains,
both of which contribute to a better understanding of gene function in a cellular and developmental setting.
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Introduction
The neural crest (NC) is a transient population of multipotent
stem cells that arises during vertebrate development. Initially
specified at the border between neural and non-neural ectoderm
at the time of the neural tube closure (embryonic day (E) 8.5 in
mice), NC cells undergo epithelial-mesenchymal transition and
migrate along divergent pathways to distinct regions of the embryo
[1,2]. During migration and at the target sites, NC cells respond to
various intrinsic and extrinsic factors that specify their differen-
tiation program into specific cell types and tissues, such as neurons
and glia of the peripheral and enteric nervous system, smooth
muscle cells of the heart outflow tract and cranial blood vessels,
chromaffin cells of the adrenal gland, melanocytes of the skin as
well as bone and cartilage of the craniofacial structures [3]. Given
their broad developmental potential and contribution to multiple
tissue and organ systems, it is not surprising that defects in genes
and genetic pathways regulating NC development result in a wide
spectrum of developmental disorders, collectively called neuro-
cristopathies. These include various human skeletal dysmorphol-
ogy syndromes (Apert syndrome and Beare-Stevenson cutis gyrata
syndrome), nervous system diseases (Hirschsprung disease) and
pigment disorders (albinism and Waardenburg syndrome) [4].
Mouse models harboring mutations in orthologous genes often
mimic these human disorders, thereby providing a valuable system
in which to dissect the pathology of neurocristopathies.
One gene associated with neurocristopathies is Sox10, a member
of the Sox family of transcription factors, which are characterized
by an Sry-type high-mobility group DNA-binding domain [5].
Sox10 expression is initiated in NC stem cells as they emerge from
the dorsal side of the neural tube and is maintained in the
melanocyte and glial lineages at later stages [6–8]. Work in mouse
and zebrafish shows that Sox10 is involved in maintenance of NC
stem cells as well as differentiation into specific lineages [9–13].
Mutations in SOX10 have been associated with Waardenburg
syndrome type II (WS2; OMIM 193519), a neurocristopathy
defined by abnormal pigmentation and hearing loss; Waardenburg
syndrome type IV (WS4; OMIM 277580), an auditory-pigmentary
disorder accompanied by loss of enteric ganglia (aganglionosis), a
feature of Hirschsprung disease [14,8,15–17]; and PCWH
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linating leukodystrophy, Waardenbrug syndrome, and Hirsch-
sprung disease), a complex neurological disorder that combines
features of four distinct syndromes (OMIM #609136) [18]. The
NC defects observed in WS4 are recapitulated in Sox10
heterozygous mice, which are viable and display hypopigmenta-
tion and aganglionic megacolon.
To identify and characterize genetic pathways required for NC
development, we utilized a whole-genome N-ethyl-N-nitrosourea
(ENU) mutagenesis screen in combination with a mouse model
heterozygous for a Sox10 mutation, Sox10
tm1Weg (herein referred to
as Sox10
LacZ) [10]. Homozygous disruption of Sox10 in Sox10
LacZ/
LacZ mice results in embryonic lethality due to impaired NC
development while heterozygous Sox10
LacZ/+ mice are viable. The
presence of a reporter gene replacing one allele of the endogenous
Sox10 in these mice allows for visualization of Sox10
LacZ expression
at different stages of embryogenesis. This provides a quick and
reliable method to screen for dominant and recessive mutations
that alter patterning of the NC lineages marked by Sox10
LacZ
expression at midgestation (E11.5), such as melanocytes and glia.
We analyzed 71 founders and identified four heritable phenotypes
that show an altered embryonic Sox10
LacZ expression pattern. One
of the mutant lines identified, msp1, was characterized by
reduction of Sox10
LacZ-expressing cells in the cranial ganglia,
cranial nerves and sympathetic chain. A complementation test
confirmed that this mutant is a new allele of the receptor tyrosine
kinase, epidermal growth factor receptor 3 (Erbb3), which carries an
amino acid substitution in the extracellular region of the protein.
Although the ENU-induced mutation does not alter expression of
the ERBB3 protein, we show that the subtle amino acid change is
sufficient to disrupt ERBB3 signaling, leading to impaired NC
development and embryonic lethality.
Results
ENU Mutagenesis to Identify Mutations Altering Sox10
Expression Pattern
To identify genes involved in NC development, we utilized an
ENU-mutagenesis screen for mutations that alter the pattern of
Sox10-expressing NC cells during mouse embryogenesis. In this
screen, ENU-treated BALB/cJ males were mated with C57BL/6J
females to generate first generation (G1) offspring (Figure S1). G1
mice were subsequently crossed with Sox10
LacZ/+ heterozygous
females, which contain a b-galactosidase reporter gene knocked
into the endogenous Sox10 locus, providing a tool to visualize
expression of NC derivatives. Second generation (G2) Sox10
LacZ/+
female offspring, which show minimal variation in hypopigmen-
tation [19], were then backcrossed to their G1 fathers, and E11.5
G3 embryos were screened for altered Sox10
LacZ expression. In
total, 71 G1 males were bred and approximately six litters of G3
offspring from each pedigree were analyzed at E11.5 when
Sox10
LacZ-expression marks the melanocyte and glial lineages of
the NC. Five of the 71 G1 pedigrees exhibited an embryonic
phenotype with an altered pattern of Sox10
LacZ-expression that was
striking in comparison to the normal variation we observe on this
mixed genetic background. Five of the 71 G1 pedigrees exhibited
an embryonic phenotype with altered patterning of Sox10
LacZ-
expressing cells. Four of these five phenotypes were reproducible
in subsequent generations indicating heritable, Mendelian pheno-
types that either directly or indirectly alter the normal pattern of
Sox10
LacZ-expression. The four loci were named modifier of Sox10
expression pattern 1–4 (msp1, msp2, msp3, and msp4; Figure 1).
Chromosomal Localization of msp Loci
The four msp pedigrees displayed a variety of phenotypes
including loss of Sox10
LacZ cells in a subset of NC lineages (msp1),
ectopic Sox10
LacZ-expressing cell masses disrupting neural tube
closure (msp2), open neural tube (msp3), and aberrant Sox10
LacZ-
expressing cells projecting from the dorsal root ganglia (DRG) over
the neural tube (msp4). A brief overview of each of these
phenotypes is presented (Figure 1, Table 1). To characterize these
msp loci, we first determined their genomic location. For msp1,
DNA from four affected G3 embryos along with three parental G2
samples was used for interval haplotype analysis [20]. Genotyping
73 simple sequence-length polymorphic (SSLP) markers spaced
throughout the genome, we observed that the msp1 phenotype
consistently segregated with the BALB/cJ allele in a 3 Mb region
distal to marker D10MIT103 on Chr 10 (Figure 2A). To confirm
linkage to this region, an additional 38 Sox10
LacZ/+ G3 embryos
were genotyped. All 12 embryos that genotyped as homozygous
BALB/cJ for this region were phenotypically affected, indicating
that the msp1 phenotype was fully penetrant. A similar mapping
strategy was used to localize msp2, msp3, and msp4 to chromosomes
11, 9, and 6, respectively (Table 1). For all four msp loci, the region
of linkage continued to segregate with the phenotype during six or
more generations of outcrossing to C57BL/6J.
Embryonic msp Phenotypes Are Recessive and Lethal
In each of the four pedigrees, the frequency of affected msp
embryos in the initial screen was consistent with a recessive mode
of inheritance. To confirm this, we analyzed embryos from a cross
using a single obligate heterozygote carrier (G1 msp/+6Sox10
LacZ/+).
In all four pedigrees, we failed to observe any affected embryos
among the embryos collected (N$20; P#0.01). Additionally, as the
pedigrees were outcrossed to C57BL/6J, phenotypically affected
embryos consistently segregated with homozygosity for BALB/cJ
alleles at the linkage regions, thus confirming that the four msp
phenotypes identified in our ENU screen were recessive. To
determine if homozygous embryos were viable, intercrosses were
established between heterozygote carriers for each of the four
phenotypes. Genotyping of viable mice at weaning age revealed no
homozygous viable mice for msp1 or msp3 indicating that these
phenotypes are fully penetrant with respect to lethality (Table 1). A
Author Summary
Genome-wide mutagenesis screens provide a valuable tool
to identify genes and genetic pathways regulating
complex developmental processes. The neural crest is a
population of multipotent cells that gives rise to many
different tissue and organ systems. Alterations in the
pathways coordinating neural crest formation lead to
human developmental disorders. To identify genetic
components involved in neural crest development, we
combined a whole-genome chemical mutagenesis ap-
proach with a mouse strain, Sox10
LacZ/+, that marks neural
crest progenitors during early embryogenesis. We identi-
fied and determined the chromosomal location of four
mutant lines that display impaired neural crest patterning.
One of the mutant lines identified carries a single amino
acid change that is sufficient to alter neural crest
development and cause embryonic lethality without
impeding upon protein expression, highlighting the
importance of the mutated residue for gene function. This
study demonstrates the feasibility of mutagenesis screens
to identify the molecular players required for neural crest
development as well as to dissect protein domain
functions.
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LacZ-Expression Pattern. An age-matched
wild-type control embryo (A, C, E, G) is shown next to a representative homozygote embryo for msp1 (B), msp2 (D), msp3 (F), and msp4 (H). The
Sox10
LacZ/+; msp1
2/2 embryos show reduction in Sox10
LacZ- expressing cells in the cranial ganglia, cranial nerves and the sympathetic ganglia (B) (red
arrowheads). Note the ectopic Sox10
LacZ-expressing masses along the dorsal surface of the neural tube in Sox10
LacZ/+; msp2
2/2 embryos (D) (red
arrowheads). Neural tube fails to close in Sox10
LacZ/+; msp3
2/2 embryos (F) (red arrowheads), thus disrupting normal Sox10
LacZ expression in
hindbrain. The Sox10
LacZ/+; msp4
2/2 embryos show aberrant Sox10
LacZ-expressing projections (H) (red arrowheads).
doi:10.1371/journal.pgen.1000177.g001
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PLoS Genetics | www.plosgenetics.org 3 September 2008 | Volume 4 | Issue 9 | e1000177Figure 2. Linkage Analysis and Molecular Characterization of the msp1 Mutation. (A) Fine mapping of the msp1 locus on mouse Chr 10.
The mutation is confined within a region distal to D10Mit103. The number of affected mice analyzed is shown below genotyping data (homozygote
black square; heterozygote white square). (B) Sequencing results of Erbb3 from control and msp1 embryos. The msp1 embryos carry an A-to-G
transition in exon 8 of the Erbb3 gene that results in change of the aspartic acid (D) to glycine (G) at position 313. (C) Position of the msp1 mutation
(D313G) in the ERBB3 protein. The ERBB3 protein consists of an extracellular region (EC), a single transmembrane-spanning region, and an
intracellular (IC) portion that contains a conserved tyrosine-kinase domain flanked by a carboxy-terminal tail with tyrosine phosphorylation sites. The
extracellular region is further subdivided into four domains: domain I, II, III, and IV. Domains I and III are homologous; domains II and IV are
homologous. ERBB3 is a kinase-deficient receptor (black X). The D313G is located in the domain II (also known as cysteine-rich region I (CR1)) of
ERBB3. In Erbb3
KO1 allele a large portion of the extracellular domain is deleted, thus forming a truncated ERBB3 protein. In Erbb3
KO2 allele no protein is
made due to the insertion of premature termination codons in all three reading frames. (D) Multiple sequence alignment of Erbb3 from various
species. The substituted aspartic acid (D313) is highly conserved among different species.
doi:10.1371/journal.pgen.1000177.g002
Table 1. Four embryonic phenotypes identified in ENU screen.
msp1 msp2 msp3 msp4
Embryonic Phenotype partial loss of Sox10 expression ectopic Sox10 expressing cells open neural tube disorganized Sox10 cell migration
Inheritance recessive recessive recessive recessive
Viability at Weaning* Lethal 0/78 Reduced Viability 6/64 (9%) Lethal 0/54 Reduced Viability 10/166 (6%)
Markers in Genome Scan 73 SSLPs 884 SNPs 77 SSLPs 58 SSLPs
# Samples in Genome Scan 71 4 1 2 1 5
Chromosome NCBI Bld. 36 Chr10 125.14–129.96 Mb Chr11 58.38–92.88 Mb Chr9 106.27–114.85 Mb Chr6 88.34–92.57 Mb
Proximal & Distal Marker D10MIT103 ter rs3697686 rs3714299 D9Mit51 D9Mit16 **rs4135401 D6Mit284
*Number of homozygote mutants observed at weaning from a heterozygote intercross established after outcrossing the G1 founder to C57BL/6J for several generations.
Expected 25% for viable phenotype.
**Sequencing revealed a nonsense mutation at nucleotide 2997G.T (NM_008881) in the Plxna1gene. Recent data suggest that this mutation is likely to cause the msp4
phenotype [44], however additional complementation testing is required.
doi:10.1371/journal.pgen.1000177.t001
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were observed at weaning, however the frequency was significantly
reduced, thus confirming that these two phenotypes are lethal with
incomplete penetrance (Table 1).
msp1 Carries a Molecular Defect in Erbb3
The region of Chr 10 in which linkage was detected for msp1
contained more than 100 annotated genes. However, we identified
the epidermal growth factor receptor 3 (Erbb3) gene as a good candidate
because the Erbb3 null phenotype, which has been previously
described, exhibits NC defects similar to those observed in the
msp1 mutants [21,22]. Erbb3, a member of the EGFR receptor
tyrosine kinase family, binds to neuregulins (NRGs) and plays an
important role in cellular processes during development and
cancer progression [23]. To determine whether an ENU mutation
in Erbb3 was responsible for the msp1 phenotype, we sequenced the
coding exons of Erbb3 from genomic DNA of an affected G3
embryo and compared it to the sequence of Erbb3 in the parental
C57BL/6J and BALB/cJ strains. Sequencing of Erbb3 in the
msp1embryos revealed only one difference, a point mutation (an A-
to-G transversion) at nucleotide 938 (GenBank NM_010153)
(Figure 2B), predicting an amino acid change from an aspartic acid
to glycine at position 313 (D313G) (NP_034283) (D313 corre-
sponds to D294 in the mature, processed protein). A multiple
sequence alignment indicated that D313 is located in domain II
(also known as cysteine-rich region 1 (CR1)) of the extracellular
portion of the protein (Figure 2C). Comparative sequence analysis
revealed that the mutated aspartic acid residue is conserved from
humans to zebrafish (Figure 2D), suggesting that this residue might
be important for the receptor function.
msp1 Is Allelic to Erbb3
To assess if the msp1 phenotype is due to the point mutation in
Erbb3,weca rr ie do utinvivocomplementation testsbetweenmsp1and
two previously described Erbb3 null alleles, Erbb3
tm1Cbm (referred to
here as Erbb3
KO1)a n dErbb3
tm2Cbm (referred to here as Erbb3
KO2) [22].
In Erbb3
KO1 mice a large portion of the extracellular region is
replaced with neomycin cassette, leading to production of a
truncated ERBB3 protein (,120 kDa), while no protein is made
from the Erbb3
KO2 allele due to introduction of the termination
codon in the extracellular portion of the gene (Figure 2C). To
determine whether msp1 complements Erbb3 null alleles, we assayed
Sox10 expression by in situ hybridization in compound heterozygous
embryos (Figure 3). At E11.5 in Erbb3
+/+ embryos, expression of
Sox10 transcript was detected in the cranial ganglia, cranial nerves,
sympathetic chain and DRG (Figure 3A). Homozygote Erbb3
KO2
(data not shown) and Erbb3
KO1 (Figure 3C) showed reduced Sox10
mRNA-expressing cells in the cranial ganglia, cranial nerves and
sympathetic ganglia while exhibiting wild-type Sox10 mRNA
expression in other NC-derived tissues, similar to msp1 embryos
(Figure 3B). Erbb3
KO1/msp1 (data not shown) and Erbb3
KO2/msp1
compound heterozygous embryos (Figure3D)also showed reduction
in Sox10-expressing cells identical to that of Erbb3
msp1 homozygotes.
These results show that Erbb3
msp1 does not complement Erbb3
KO1 or
Erbb3
KO2 phenotypes, demonstrating thatthe NCdefectsobserved in
msp1 embryos are due to the mutation in Erbb3.
We further investigated the timing of the NC defects in
Erbb3
msp1/msp1 embryos by analyzing Sox10 expression earlier in
development. At E9.0 (18 somite stage) Sox10 expression was
already reduced in trigeminal (V), geniculate (VII), and acoustic
(VIII) ganglia of Erbb3
msp1/msp1 embryos (Figure 4), indicating that
the NC defect in the Erbb3
msp1/msp1 embryos is evident as early as
E9.0. This data are consistent with the timing of NC defects
reported for Erbb3 null alleles [24,25,22].
Tofurthercomparethe phenotypesofmsp1tonullallelesofErbb3,
embryonic lethality was assessed in msp1 embryos. Dissection of
embryos generated from several independent Erbb3
msp1/+ intercross-
es indicated that Erbb3
msp1/msp1 embryos were present at expected
numbers at E11.5, in accordance with the Mendelian ratio of 25%
(Table S1). However, the number of Erbb3
msp1/msp1 embryos was
dramatically reduced between E12.5 (N=15, 17%) and E13.5
(N=6, 8%). No live embryos were observed at weaning stage. These
results demonstrate that homozygosity for Erbb3
msp1 causes embry-
onic lethality, with the majority of mutant embryos dying by E13.5.
The frequency of weaned heterozygous animals was 65%, indicating
there was no lethality associated with heterozygosity. The viability
data observed for Erbb3
msp1 are consistent with viability data
previously shown for Erbb3
KO1/KO1 and Erbb3
KO2/KO2 animals [22].
Taken together, our data support the hypothesis that even though
the Erbb3
msp1 allele carries a single amino acid alteration, this point
mutation significantly impairs Erbb3 such that this allele phenotyp-
ically resembles Erbb3 null alleles.
Erbb3 mRNA and Protein Are Expressed in the msp1
Embryos
To determine the mechanism by which the msp1 mutation
impairs the receptor function, we first examined structural models
of mouse ERBB3 and the msp1 mutant. Molecular modeling based
on the solved three-dimensional structure of the human ERBB3
extracellular domain indicated that residue D313 is located in the
CR1 of domain II. Introduction of the msp1 missense mutation is
not predicted to destabilize the structure or alter any pairwise
interactions in the theoretical model (Figure 5A, B). However, the
msp1 substitution of glycine for aspartic acid at position 313 leads
to a loss of negative charge on the molecule’s surface (Figure 5C,
D). The impact of this change on the local surface charge
distribution, in a region distal to residues that interact with a
ligand or are directly involved in receptor dimerization, is unclear.
Since the results of structural modeling suggested no significant
impactonreceptorstructureorfunction,wenextevaluatedtheaffect
of the msp1 mutation on Erbb3 mRNA and/or protein expression.
Erbb3 mRNAexpression wasexamined byErbb3 whole-mount in situ
analysis (Figure 6 A–F). In situ hybridization revealed that Erbb3
transcript was expressed in DRG and somites in Erbb3
msp1/msp1
mutants, but reduced in the cranial ganglia, cranial nerves, and
sympathetic ganglia, indicating that the ENU mutation does not
significantly alter Erbb3 levels. Next, ERBB3 protein expression was
evaluated by immunoblotting using an antibody that specifically
recognizes the carboxy-terminus of the protein (C-17). A full-length
ERBB3 protein (180 kDa) was observed in Erbb3
msp1/msp1 whole
embryo lysates at E11.5 (Figure 6G). Lysates collected from
Erbb3
KO2/KO2 embryos served as a negative control and showed no
ERBB3 expression (Figure 7B). No significant differences in levels of
protein expression were detected between control, Erbb3
msp1/+,a n d
Erbb3
msp1/msp1 lysates. All together, these results indicate that the
mutation does not interfere with the Erbb3 transcripts or protein
translation.
NRG1-b1-Induced Phosphorylation of Erbb3 is Impaired
in the msp1 Embryos
To further examine the mechanism by which Erbb3
msp1 disrupts
ERBB3 signaling, ligand-induced activation of ERBB3 was
examined. Upon ligand binding, ERBB3 undergoes dimerization
with a co-receptor (the most common being ERBB2), and this
dimerization promotes phosphorylation of ERBB3 intracellular
tyrosine residues. As phosphorylation of tyrosine residues is an
indicator of the receptor’s ability to become activated and is a
Neural Crest Mutagenesis Screen
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phosphorylation status was examined in Erbb3
msp1/msp1 embryonic
cells. Erbb3
msp1/+ intercrosses were established, and embryos were
collected at E11.5. Embryonic cells were isolated from whole
E11.5 embryos, grown in culture for 24 hours and then treated
with NRG1-b1 for 10 minutes. Upon NRG1-b1 stimulation,
ERBB3 phosphorylation was detected in Erbb3
+/+ and Erbb3
msp1/+
cultures, while no ERBB3 phosphorylation was observed in
Erbb3
msp1/msp1 cells (Figure 7A). This lack of ERBB3 tyrosine
phosphorylation in Erbb3
msp1/msp1 cells could be due to altered
ERBB3 function as a result of the msp1 mutation, or could reflect
the absence of cells that are able to respond to NRG1-b1 stimulus,
such as the cranial and sympathetic ganglia. To test the latter
hypothesis, we evaluated ERBB3 phosphorylation in Sox10
LacZ
homozygous mutants. Sox10
LacZ homozygotes show reduced Erbb3-
expressing cells in DRG, cranial and sympathetic ganglia, but
Erbb3 expression persists in somites (similar to Erbb3 expression in
somites and DRG in Erbb3
msp1/msp1 embryos, Figure 6B, D, and F)
(Britsch et al., 2001). Analysis of ERBB3 tyrosine phosphorylation
in Sox10
LacZ homozygous cultures indicated that ERBB3 becomes
phosphorylated in the presence of NRG1-b1 (Figure 7B),
suggesting that the remaining Erbb3-expressing cells in Sox10
mutants are sufficient to respond to NRG1-b1 stimuli. Therefore
the absence of ERBB3 phosphorylation in the Erbb3
msp1/msp1
cultures is not due to a lack of NRG1-responsive cells, but rather
to msp1-induced alteration of ERBB3 function.
To determine whether the msp1 mutation prevents ERBB3
surface expression, we used a cell surface biotinylation assay on
primary embryonic cell cultures. Embryonic cell cultures derived
from several independent Erbb3
msp1/+ intercrosses were stimulated
Figure 3. Complementation Test between msp1 and Erbb3 Null Allele in Mice. Heterozygous msp1/+ mice were mated with Erbb3
KO1/+ and
Erbb3
K02/+ mice to generate compound heterozygote embryos. Sox10 expression was analyzed in control (A), msp1 (B), null (C), and compound
heterozygous embryos (D) at E11.5 by in situ hybridization. The mutant genotypes tested showed reduced expression of the Sox10 transcript in the
cranial ganglia, cranial nerves and sympathetic ganglia (red arrowheads). Lack of complementation of Sox10 expression pattern in the compound
heterozygous embryos confirmed that msp1 is allelic to Erbb3. The Sox10-expressing structures in the Erbb3
+/+ embryo are: maxillary nerve (MN), facial
nerve (FN), cervical plexus (CP), forelimb plexus (FP), dorsal ramus (DR), sympathetic ganglia (SG), trigeminal ganglia (V), geniculate ganglia (VII),
acoustic ganglia (VIII), superior ganglia (IX), jugular ganglia (X), accessory nerve (AN) and otic vesicle (OV).
doi:10.1371/journal.pgen.1000177.g003
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and mutant cell lysates were immunoprecipitated with avidin-
conjugated beads and further analyzed by Western blotting. When
membranes were probed with the anti-ERBB3 antibody, the band
corresponding to the ERBB3 protein was detected in the surface
fraction of the msp1 cultures (Figure 7C), indicating that ERBB3 is
expressed on the cell membrane. Nonetheless, the band appeared
slightly less intense when compared to wild-type. Analysis for
tubulin in these samples validated the absence of intracellular
protein biotinylation in the surface fraction (Figure 7C). Next, we
evaluated the phosphorylation status of ERBB3 in the surface
fraction using anti-phospho ERBB3 antibody. While ligand-
induced phophorylation of ERBB3 was consistently detected in
the avidin-precipitated fractions of wild-type cultures, only trace
amounts of phosphorylation was observed in the msp1 embryonic
cells (Figure 7D). These results indicate that although the majority
of ERBB3 is expressed on the cell surface, the mutant receptor is
still insufficiently phosphorylated. Interestingly, when Erbb3
msp1
and Erbb2 were transiently overexpressed in 293T cells, ERBB3
became phosphorylated in a ligand-dependent manner (Figure
S2). Collectively, this suggests that Erbb3
msp1 is a hypomorphic
allele and that forced overexpression of the mutant protein can
overcome the severe reduction in ERBB3 phosphorylation that we
observe in vivo.
Discussion
Sox10 Expression Screen Identifies Loci Essential for NC
Development
A whole-genome ENU mutagenesis screen was designed to
identify mutations that alter patterning of Sox10-expressing NC
derivatives. In the first 71 G1 lines analyzed, we mapped four
heritable phenotypes that disrupt NC development. The frequency
of phenotypes identified in our screen (6%) is consistent with
previously published embryonic, phenotype-driven screens [26–
30]. The variation in the frequency (3%–28%) reported in these
screens is likely due in part to variations in the specificity of the
phenotype being screened for as screens for gross morphology
have produced a higher frequency of phenotypes than very
focused, tissue specific screens.
One particular mutant line, msp1, identified in our screen,
showed altered Sox10
LacZ patterning only in the cranial and
Figure 4. Expression Analysis of Endogenous Sox10 Transcript at E9.0. In Erbb3
+/+ (A, B), Sox10-expressing cells are found in the cranial
ganglia and DRGs. In Erbb3
msp1/msp1 (C, D), Sox10-expressing cells are detected in DRG but reduced in the cranial ganglia (red arrowheads). Labeled
are trigeminal ganglia (V), geniculate and acoustic ganglia (VII/VIII), superior and jugular ganglia (IX/X) and the otic vesicle (OV).
doi:10.1371/journal.pgen.1000177.g004
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demonstrated that DRG, enteric ganglia and melanocytes are not
affected in the msp1 mutants at E11.5, confirming that the ENU-
induced mutation disrupts a specific subset of NC-derived cells.
Through linkage analysis, sequencing, and complementation, we
confirmed that the msp1 phenotype is due to a point mutation in
Erbb3, a member of the EGFR receptor tyrosine kinases family.
The identification of the Erbb3 allele in our Sox10
LacZ expression
screen indicates that we can successfully identify genes essential for
Sox10-expressing cell lineages.
Erbb3
msp1 Is a Novel Allele of Erbb3
Previously, two different null alleles of Erbb3, Erbb3
KO1 and
Erbb3
KO2, have been generated using gene-targeting technology
[22]. Erbb3
KO1 mice produce truncated protein (,120 kDa), while
no protein is made from the Erbb3
KO2 allele. Animals homozygous
for Erbb3
KO1 or Erbb3
KO2 allele are embryonic lethal due to cardiac
malformation and show severe defects in development of the
peripheral nervous system. In this study, we demonstrated that the
msp1 is a novel allele of Erbb3, Erbb3
msp1, that carries a single amino
acid substitution in the extracellular region of the protein. Unlike
the null alleles, the full-length ERBB3 protein (,180 kDa) is
present in the msp1 mutants. We showed that msp1 failed to
complement either of Erbb3 null alleles, confirming that the msp1
phenotype is indeed due to a molecular lesion in Erbb3. The onset
of NC defect in msp1 mutants is evident prior to E9.0, consistent
with the data reported for Erbb3 null mice. Furthermore, the msp1
embryos die during gestation around E13.5 (Table S1), which is in
accordance with the lethality data reported for Erbb3
KO1 and
Erbb3
KO2 alleles [22]. While we could not detect any differences in
Figure 5. Modeling the msp1 Mutation. Structural models of mouse wild type (A) and msp1-mutant (B) ERBB3 extracellular domains in the
‘‘closed’’ conformation. Negatively charged residues are shown in red, while positively charged residues are marked in blue. Protein domains I, II, III,
and IV are labeled in yellow. The region of the msp1 mutation (yellow square) is located in domain II. C and D show close-up views of the regions
denoted by the yellow squares in panels A and B. The msp1 mutation results in the loss of negative charge on the surface of the molecule. The bulky,
negatively charged aspartic acid in the wild type protein is shown in red in panel C. This aspartic acid was replaced by glycine (a small, non-polar
amino acid), shown in yellow in panel D.
doi:10.1371/journal.pgen.1000177.g005
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cannot rule out the possibility that differences may occur in
phenotypes not examined in this study. Nonetheless, our results
indicate that the single amino acid change in msp1 is sufficient to
disrupt NC development and cause embryonic lethality without
interfering with ERBB3 expression.
How Does D313G Disrupt ERBB3 Function?
The finding that Erbb3 mRNA and protein are present in msp1
embryos, indicates that the ENU-induced mutation does not
disrupt Erbb3 transcription or translation. Comparative amino
acid sequence analysis showed that the mutated amino acid (D313)
is conserved among multiple species, suggesting that this residue
Figure 6. Erbb3 mRNA and Protein Expression in msp1 Mutants. Lateral view of Erbb3 whole-mount in situ hybridization in control (A) and
Erbb3
msp1/msp1 (B) embryos at E11.5. In control embryos, Erbb3 transcript was detected in the cranial ganglia, cranial nerves (C), DRG, sympathetic
ganglia (SG), and somites (SO) (E). The Erbb3
msp1/msp1 embryos showed absence of the Erbb3 transcript in the trigeminal (V), superior (IX), and jugular
(X) ganglia, accessory nerve (AN) and in the sympathetic chain (red arrowheads in D and F). Erbb3 remained expressed in DRGs and somites in the
msp1 embryos. (G) Immunoblot analysis of the ERBB3 protein expression using the C-17 antibody specific for carboxy terminus of ERBB3 in Erbb3
+/+,
Erbb3
msp1/+ and Erbb3
msp1/msp1 whole-embryo lysates.
doi:10.1371/journal.pgen.1000177.g006
Neural Crest Mutagenesis Screen
PLoS Genetics | www.plosgenetics.org 9 September 2008 | Volume 4 | Issue 9 | e1000177could be critical for receptor activity. Indeed, biochemical analysis
of receptor function revealed that ligand-induced phosphorylation
of ERBB3 is disrupted in Erbb3
msp1/msp1 embryonic cell cultures
(Figure 7A and D). Interestingly, we did observe ligand-dependent
ERBB3 phosphorylation after transient co-expression of Erbb3
msp1
and Erbb2 in 293T cells (Figure S2), indicating that the mutant
ERBB3
msp1 is a severe hypomorphic allele that can become
phosphorylated in vitro. As previous studies have shown, the
difference in the phophorylation status could be attributed to
differences in the efficiency of protein processing and post-
translation modification in 293T cells compared to our embryonic
cell cultures [31–33].
The loss of ligand-induced ERBB3 phosphorylation observed in
themsp1 embryoscouldbeexplainediftheERBB3proteinexpressed
in msp1 embryos was not properly trafficked to the cell surface.
However, our cell surface biotinylation assay showed that ERBB3 is
expressed on the cell membrane in the msp1 mutants. We
consistently observed a small reduction in surface ERBB3 in the
msp1 embryonic cell cultures, implying that a small proportion of the
mutant protein may not be properly folded and trafficked to the cell
membrane. While additional studies are needed to conduct a more
extensive analysis of the msp1-induced effect on ERBB3 stability and
conformation, embryonic cell cultures are not the optimal system to
address these questions due to the heterogeneous cell populations
present in the wild-type and mutant cultures.
Although ERBB3 is expressed on the cell surface, it still remains
insufficiently phosphorylated in the mutant embryos (Figure 7D).
A second possibility that could contribute to impaired ERBB3
phosphorylation is that the D313G mutation might disrupt the
ability of the ERBB3 protein to dimerize with its binding partner
and/or bind to a specific ligand (Figure 8). ERBB3 lacks kinase
activity due to evolutionary substitutions of critical residues within
its catalytic domain [34], and thus can only signal within the
context of a receptor heterodimer [35]. In the absence of NRG1,
ERBB3 acquires a ‘‘tethered’’ conformation, which renders the
receptor inactive. Previous structural studies proposed that, in this
conformation, domains I and III are interlocked, thus preventing
receptor dimer formation [36]. Furthermore, the dimerization
arm, a ten-amino acid loop located in domain II (residues 242–259
of ERBB3), is bound to domain IV and, therefore, is unable to
interact with another receptor. Upon ligand binding, the ERBB3
receptor undergoes a conformational change that allows for
heterodimerization to occur. At the center of the dimer interface is a
dimerization arm that reaches across and interacts with the
dimerization arm of another receptor. The dimerization arm is
conserved in all ERBB receptors, and deletions or mutations of these
residues have been shown to completely abolish ligand-induced
activation of EGFR [37,38]. The msp1 mutation is within domain II
(CR1)of the extracellular region of the receptor. Since this domainis
required for the receptor dimerization, one might predict that this
mutation indirectly interferes with the ability of the receptor to
dimerize with its dimerization partner. It is interesting to note that
D313 is located in close proximity to E311 (D313 corresponds to
E292 in the mature, processed protein) (Figure 5D). E311 of ERBB3
corresponds to EGFR residue E317 (E293 in the mature protein),
and previous studies with EGFR have shown that upon ligand
binding E317 forms a salt bridge with a residue in domain III,
facilitating receptor dimerization [39]. Given the close proximity of
D313 and E311 in ERBB3, it is possible that the D313G mutation
interferes with salt bridge formation, thus destabilizing the
Figure 7. NRG1-b1-Induced Phosphorylation Is Impaired in ERBB3
msp1/msp1 Embryonic Cell Cultures. (A) Cells isolated from E11.5 embryos
generated from Erbb3
msp1 heterozygous crosses were stimulated with or without NRG1-b1 (5 ng/ml) for 15 minutes, and cell extracts were collected.
Equal amounts of proteins (20 ug) were separated on 8% SDS-PAGE gel, and membranes were blotted with the phospho-ERBB3, ERBB3 and a-Tubulin
specific antibodies. NRG1-b1-induced phosphorylation of ERBB3 was detected in Erbb3
+/+ and Erbb3
msp1/+ cell cultures. In the absence of NRG1, no
phosphorylation of ERBB3 was detected in these cells. Erbb3
msp1/msp1 cultures treated with NRG1-b1 revealed no band corresponding to the
phosphorylated form of ERBB3. (B) Analysis of ERBB3 phosphorylation in Sox10
LacZ/LacZ and Erbb3
KO2/KO2 embryonic cell cultures. In the presence of NRG1-
b1, phosphorylation of ERBB3 was observed in Sox10 mutant cultures, while no NRG1-b1-induced phosphorylation was detected in Erbb3
KO2/KO2
embryonic cells. (C) Cell surface biotinylation assay.ERBB3 was detectedin total lysate (L), intracellular fraction (I) and surface fraction (S) inbo thwi ld -t yp e
and mutant embryonic cell cultures stimulated with NRG1-b1. No intracellular proteins were detected in the surface fraction of immunoprecipitates as
indicated byanti-Tubulin immunoblotting. (D) Analysis of ERBB3 phosphorylation in avidin-precipitated fractionsof embryoniccell cultures (1 mgo ft o t a l
lysates precipitated and loaded on the gel). Dramatically reduced ERBB3 phosphorylation was detected in the msp1cultures.
doi:10.1371/journal.pgen.1000177.g007
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dimerization. However, we cannot exclude the possibility that the
mutation may allosterically disrupt the ability of the receptor to bind
to NRG1. While structural modeling provided no clear evidence of
either effect, the inability of the ERBB3 receptor to bind to a ligand
and/or to dimerize with its dimerization partner would be sufficient
to disrupt ligand-induced phosphorylation and impair NRG1/
ERBB3 signaling.
This study provides the first evidence of the importance of the
aspartic acid residue at position 313 for ERBB3 receptor function.
The identification of a novel Erbb3 point mutation that alters NC
development and leads to embryonic lethality demonstrates the
feasibility of ENU-induced variations to help dissect the function of
specific protein domains and provide information beyond what can
be obtained from studying null alleles. Analysis of this and other
mutant loci identified in our screen will shed additional functional
insights into the molecular pathways governing NC development.
Materials and Methods
Mouse Husbandry
BALB/cJ and C57BL/6J inbred mouse strains were purchased
from Jackson Laboratories (Bar Harbor, ME). Engineered mice
with a LacZ cassette replacing the endogenous Sox10 locus
(Sox10
LacZ/+; Britsch et al., 2001) were obtained on a mixed genetic
background and maintained at NHGRI by crossing to C57BL/6J
for several generations. All other mice described in the ENU
screen were bred and housed in the NHGRI animal facility
according to NIH guidelines. For genotyping, genomic DNA was
prepared from tail biopsies or yolk sacs using a PUREGENE DNA
purification kit (Gentra Systems, Inc. Minneapolis, MN) according
to the manufacturers instructions. Noon on the day of vaginal plug
observation was designated E0.5 for timed pregnancies. Reab-
sorbed embryos were counted as dead in analysis of lethality data.
ENU Treatment and Mutagenesis Screen
ENU was prepared and injections were carried out as previously
described [19].Briefly, ENU (Sigma; St. Louis, MO) was dissolved at
100 mg/ml in 95% ethanol and diluted to 5 mg/ml in a sterile
phosphate/citrate buffer (0.1 M dibasic sodium phosphate, 0.05 M
sodium citrate, pH 5.0). A spectrophotometer reading at a
wavelength of 398 nm was used to confirm the ENU concentration,
and BALB/cJ male mice were given weekly intraperitoneal
injections at 0.1 mg per gram of body weight for three consecutive
weeks. Mice were allowed to recover for eight weeks post-injection
and loss of fertility was confirmed by mating to C57BL/6J females.
Males that lost and subsequently regained fertility (G0)w e r eb r e dt o
C57BL/6J females beginning at 12 weeks post-injection and the
resulting first generation male progeny (G1) were crossed to
Sox10
LacZ/+ females. In the next generation, female Sox10
LacZ/+
offspring (G2) werebackcrossedto theirG1 fathers,andembryos(G3)
were harvested at E11.5 for b-galactosidase staining.
Mapping
The number of samples and markers used in the initial genome
scan for each pedigree is provided in Table 1. In each case DNA
from affected G3 embryos and G2 obligate carriers was used for
genotypingatsimplesequencelengthpolymorphism(SSLP)orsingle
nucleotide polymorphism (SNP) markers spaced throughout the
genome. The markers were polymorphic between the BALB/cJ and
C57BL/6J parental strains used in this study and were genotyped by
gel electrophoresis following PCR amplification (SSLPs) or using the
Sentrix Universal Array Matrix platform (Illumina, San Diego, CA)
(SNPs). Following the initial genome scan, additional markers from
regions of significant linkage were used to refine the location of each
msplocusandgenotypeadditional G2 and G3animals.Subsequently,
markers flanking each locus (Table 1) were used to identify viable
heterozygous carriers and maintain the line during six or more
subsequent generations of outcrossing to C57BL/6J.
DNA Sequencing
Using a candidate gene approach, Erbb3 was chosen for
sequencing in the msp1 pedigree. Each exon and surrounding
splice sites were amplified from genomic DNA for sequencing
using standard techniques (Harvard Partners Healthcare Center
for Genetics and Genomics, Harvard Medical School). The
Figure 8. Proposed Mechanism by which the msp1 Mutation Disrupts ERBB3 Function. In the absence of ligand (left), ERBB3 acquires a
‘‘tethered’’ conformation that renders the receptor inactive [36]. Upon ligand binding, the receptor undergoes a conformational change to allow
dimerization with its binding partner, ERBB2 (right). Heterodimerization leads to autophosphorylation of ERBB2 and transphosphorylation of the
kinase-dead ERBB3 receptor [34]. Phosphorylated tyrosine residues activate downstream signaling pathways, which elicit diverse cell responses.
Ligand-induced phosphorylation of ERBB3 is impaired in the msp1 (red Xs). The D313G mutation (red asterisk) may interfere with the receptors
surface expression, ligand binding, and/or heterodimerization with ERBB2.
doi:10.1371/journal.pgen.1000177.g008
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msp1 mutant was compared to sequence from the parental inbred
strains to identify a single nucleotide change on the ENU treated
chromosome.
TaqMan Assay for msp1 Genotyping
Taqman MGB probes (Applied Biosystems, Foster City, CA)
were designed across the site of the msp1 mutation specific for both
the wild-type allele (FAM-TGG-AAG-TAG-a-TAA-GAA-TG)
and the ENU induced mutant allele (VIC-TGG-AAG-TAG-g-
TAA-GAA-T). PCR reactions were carried out in 26 GenAmp
PCR Master Mix, 10 mM each primer (primer 1: AGG-GCT-
TGT-CCT-GCT-GAC-AA and primer 2: TGC-AAG-GCT-
CAC-ACA-TCT-TGA), and 100 nM each allele-specific probe.
Cycling conditions were 2 minutes at 50uC, 10 minutes at 95uC,
followed by 40 cycles of 92uC for 15 seconds and 60uC for
1 minute. Relative quantitation of the two alleles was determined
in an end-point assay for genotyping.
b-Galactosidase Staining
Dissected embryos were fixed in 16phosphate buffered saline
(PBS), 1% formaldehyde, 0.2% glutaraldehyde, 0.02% NP-40 for
2 hours on ice, and X-gal staining was performed as previously
described [40].
Whole-Mount In Situ Hybridization
Whole-mount in situ hybridization was performed using digox-
igenin-labeled antisense probes as previously described [41].
Reverse-transcribed digoxigenin-conjugated probes were made from
linearized plasmids with polymerase binding site linkers (all reagents
from Roche Diagnostic Incorporation, Indianapolis, IN). The
following DNA sources were used for probe synthesis: 1.5-kb Sox10
(nucleotides 1287–2787, dcgs10 BssHII T7 RNA polymerase), and
Erbb3 [42] (EcoRI, T7 RNA polymerase).
Embryonic Cell Culture
Timed pregnancies between Erbb3
msp1/+ heterozygote mice were
established and embryos were dissected out at E11.5. The yolk sac
was stored for DNA isolation and used for genotyping of the msp1
mutation. Dissected embryos were dissociated using a sterile razor
blade, and digested in 0.05% Trypsin-EDTA for 30 minutes at
37uC. The trypsin digestion was inactivated with DMEM medium
supplemented with 10% fetal bovine serum. To obtain single-cell
suspension, digested embryos were pipeted up and down several
times using a 2-ml pipet. The cell suspensions were transferred to a
15 ml conical tubes and spun down for 5 minutes at 12006g.
Supernatant was carefully removed, and cell pellet was resus-
pended in fresh DMEM medium supplemented with 10% fetal
bovine serum, 10 nM Endothelin 3 (Sigma), 50 ng/ml Stem cell
factor (R&D Systems, Minneapolis, MN) and 10 ng/ml Wnt-3a
(R&D Systems) and cultured for 24 hours at 37uC and 5% CO2.
The following day, cultures were stimulated with 5 ng/ml NRG1-
b1 (R&D Systems) for 15 minutes and lysed in RIPA lysis buffer
[1XTBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
0.004% sodium azide] supplemented with 2 mM sodium ortho-
vanadate, 4 mM phenylmethylsulfonyl fluoride, and protease
inhibitor cocktail (Santa Cruz Biotechnology).
Structural Modeling
Molecular modeling of the mouse ERBB3 extracellur region
was performed using the MODELLER package [43] as imple-
mented within Discovery Studio (Accelrys, San Diego, CA).
Modeling was based on the solved structure of human ERBB3, as
determined at a resolution of 2.6 A ˚ by X-ray diffraction
(pdb|1M6B) [36]. The mouse sequence was aligned with the
human template sequence using Clustal W. The two sequences
share 92% residue identity over the region modeled. To generate
wild type and mutant structures, the MODELLER program was
run in a fully-automated mode with a high optimization level in
order to construct energy-minimized three-dimensional models of
the aligned target sequences by satisfaction of spatial restraints
extracted from the template PDB file.
Immunoblot Analysis
Whole embryo lysates were prepared as follows. E11.5 embryos
were dissected out and homogenized in RIPA lysis buffer
supplemented with 1 mM Na4P2O7, 2 mM PMSF and protease
inhibitor cocktail (Santa Cruz Biotechnology, Santa Cruz, CA)
followed by a brief sonication. The lysates were cleared by
centrifuged at 14,0006g for 10 minutes at 4uC, and protein
concentration of the supernatant was determined using a BCA
protein assay kit (Pierce, Rockford, IL). Cell lysates containing
equal amounts of protein were separated on 8% Tris-Glycine SDS
gel (Invitrogen, Carlsbad, CA), transferred to polyvinylidene
fluoride membrane (Invitrogen) and blocked with 5% milk in
TBST [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.05% Tween
20] for 1 hour at room temperature. The membranes were then
incubated with primary antibody against ERBB3 (1:1000 diluted
in 5% milk in TBST) (Santa Cruz Biotechnology; C-17), phospho-
ERBB3 (1:500 diluted in 5% bovine serum albumin (BSA) in
TBST) (Cell Signaling, Santa Cruz, CA; 21D3), a-Tubulin (1:1000
diluted in 5% milk in TBST) (Sigma) at 4uC over night. After
washing in TBST, the membranes were incubated with horserad-
ish peroxidase-conjugated secondary antibodies (1:10,000) (Amer-
sham Biosciences, Little Chalfont, UK) for 1 hour at room
temperature. The protein bands were detected using an enhanced
chemiluminescence kit (Millipore, Billerica, MA).
Cell Surface Biotinylation Assay
Embryonic cell cultures were prepared as described above. On
day two, cultures were stimulated with NRG1-1b for 10 minutes,
washed twice in 16PBS and chilled on ice for 5–10 minutes. Cell
surface proteins were labeled with 1 mg/ml EZ-Link Sulfo-NHS-
SS-Biotin (Pierce, Rockford, IL) in PBS for 30 minutes at 4uC with
gentle shaking. Biotin was aspirated and cultures were washed
twice for 3–5 minutes with 100 mM Tris, pH 8.0 in PBS followed
by one wash in 16PBS. Cells were solubilized in mild-lysis buffer
(20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 1% NP-40,
10% glycerol) supplemented with 1 mM Na4P2O7, 2 mM PMSF
and protease inhibitor cocktail (Santa Cruz Biotechnology, Santa
Cruz, CA) for 30 minutes at 4uC on a shaker, and centrifuged for
15 minutes at 10,0006g. Supernatants were removed and the
protein concentration determined by a BCA protein assay kit
(Pierce, Rockford, IL). An equal amount of protein (1 mg) of each
genotype was precipitated with 100 ul NeutrAvidin agarose beads
(Pierce, Rockford, IL) overnight at 4uC with rotation. Beads were
washed three times in mild-lysis buffer, and surface proteins were
eluted in 50 ul 26SDS loading buffer supplemented with 50 mM
DTT (Invitrogen, Carlsbad, CA). Equal volumes (40 ul) of each
genotype were separated on 8% Tris-Glycine SDS gel, and
membranes were blotted with anti-ERBB3 and/or phospho-
ERBB3 antibody.
Site-Directed Mutagenesis
The msp1 mutation was introduced in the human Erbb3 cDNA
(Clone ID #6147464, Open Biosystems, Huntsville, AL) via
QuickChange II Site-Directed Mutagenesis Kit according to
Neural Crest Mutagenesis Screen
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following PCR primers were used to introduce the mutation:
Fwd-CCTGACAAGATGGAAgTAGGTAAAAATGGGCTCA-
AGATG- and Rev-CATCTTGAGCCCATTTTTACCTACTT-
CCATCTTGTCAGG-. The presence of the msp1 mutation was
confirmed by sequencing.
Cell Culture and Transfection
293T cells were cultured in DMEM medium with 10% fetal
bovine serum, 100 units/ml penicillin and 100 ug/ml streptomy-
cin at 37uC in a humidified 5% CO2. Erbb3
msp1 and Erbb2 (Clone
ID #6178526, Open Biosystems) or wild-type Erbb3 and Erbb2
clones were co-expressed in 293T cells using FuGENE 6 (Roche
Applied Science) transfection reagent. 48 hours post-transfection,
cells were starved overnight in serum-free DMEM. The following
day, cells were stimulated with or without 5 ng/ml NRG1- b1
(R&D Systems) for 15 minutes. Cell lysates were collected in RIPA
lysis buffer and analyzed by Western blotting.
Supporting Information
Figure S1 Schematic representation of the embryonic ENU
screen for the recessive mutations that alter Sox10
LacZ expression.
ENU treated BALB/C males are mated with C57BL/6J female to
generate G1 offspring. G1 males are further crossed with
Sox10
LacZ/+ females to obtain G2 progeny. G2 Sox10
LacZ/+ females
are backcrossed to G1 mutagenized males. The resulting G3
embryos are collected at E11.5, stained for b-galactosides activity,
and analyzed for altered Sox10
LacZ expression.
Found at: doi:10.1371/journal.pgen.1000177.s001 (3.47 MB TIF)
Figure S2 Ligand-induced Phosphorylation of Erbb3
msp1 in 293T
Cells. 293T cells were cotransfected with Erbb2 and Erbb3 or with
Erbb2 and Erbb3
msp1 cDNA. Subsequently, cells were stimulated
with NRG1-b1 and harvested for immunoblot analysis. NRG1-
b1-induced phosphorylation of ERBB3 was detected and com-
pared between cells transfected with wild-type ERBB3 and cells
transfected with the msp1 mutant ERBB3.
Found at: doi:10.1371/journal.pgen.1000177.s002 (0.1 MB TIF)
Table S1 Embryonic and postnatal viability of the msp1 mutants.
Found at: doi:10.1371/journal.pgen.1000177.s003 (0.03 MB
DOC)
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